No Exports to Europe or Israel in Q4, Maybe 2021BUSINESS DEVELOPMENTS
(a) EU Export In February 2020, Zenabis received an export license from Health Canada to export cannabis for medical purposes to the EU, with which it intends to supply pharmaceutical-grade cannabis products to the EU market. Zenabis shipped the initial test shipment to its EU partner in April 2020. In May 2020, the Company announced that it has successfully received European Union Good Manufacturing Practices ("EU GMP") approval for its Atholville Facility and expects to commence recurring commercial exports to the European Union in the fourth quarter of 2020, or first quarter of 2021 with regional sales in Europe by ZenPharm commencing in the first quarter of 2021.
(b) Israel Export In March 2020, Zenabis received an initial purchase order for bulk dried cannabis from a certified importer located in Israel, and obtained an export license from Health Canada to export cannabis for medical purposes in April 2020. Since the initial shipment in May 2020, the Company has made multiple significant shipments to Israel with repeat orders from the same customer. The Company notes that due to changes in regulations in Israel during Q4 2020 pertaining to the import of cannabis products, shipments to Israel are not likely to occur during Q4 2020 but are expected to resume in Q1 2021.